IRL-1620 对缺血后脑损伤作用的系统评价与实验研究 Meta 分析
该系统评价与 Meta 分析遵循 PRISMA 指南,检索 MEDLINE(PubMed)和 Scopus 数据库截至 2022 年 12 月的文献,并筛查 ClinicalTrials.gov 与 Pharmazz Inc. 的未发表或进行中试验,仅评估英文研究。最终纳入 7 项研究,均为动物大鼠模型;其中 6 项大脑中动脉闭塞(MCAO)模型研究进入 Meta 分析。在评估死亡率的 2 项研究中,IRL-1620 组 MCAO 后 24 h 无死亡报告,而溶媒组死亡风险几乎高 5 倍(风险比 5.3,95%CI 0.7-40.1,I²=0%)。全部 5 项评估 MCAO 后第 7 天结局的研究显示,与溶媒相比,IRL-1620 与统计学显著更低的神经功能缺损和更好的运动表现相关;梗死体积、神经祖细胞分化潜能和线粒体命运也随 IRL-1620 给药改善。作者结论认为,在动物 MCAO 模型中 IRL-1620 增强神经发生和神经保护并改善结局,未来需在人急性缺血性卒中及心脏骤停等其他常见脑缺血病因中扩展研究。
要点
- 在 2 项评估死亡率的研究中,IRL-1620 组 MCAO 后 24 h 无死亡报告,溶媒组死亡风险几乎高 5 倍(风险比 5.3,95%CI 0.7-40.1,I²=0%),未达统计学显著。
- 在全部 5 项评估 MCAO 后第 7 天结局的研究中,与溶媒相比,IRL-1620 与统计学显著更低的神经功能缺损和更好的运动表现相关。
- IRL-1620 给药还改善梗死体积、神经祖细胞分化潜能和线粒体命运。
- 纳入的 7 项研究均为动物大鼠模型,其中 6 项 MCAO 模型研究进入 Meta 分析。
- 作者结论认为,在动物 MCAO 模型中 IRL-1620 增强神经发生和神经保护并改善结局,未来需在人急性缺血性卒中及心脏骤停等其他常见脑缺血病因中进一步研究。
适用人群与场景
- 动物大鼠模型,其中 6 项为大脑中动脉闭塞(MCAO)模型研究进入 Meta 分析;7 项纳入研究均为动物大鼠模型。
研究设计与关键结果
- 系统评价与 Meta 分析,最终纳入 7 项研究,均为动物大鼠模型;6 项 MCAO 模型研究进入 Meta 分析。
- 在 2 项评估死亡率的研究中,IRL-1620 组 MCAO 后 24 h 无死亡报告,溶媒组死亡风险几乎高 5 倍(风险比 5.3,95%CI 0.7-40.1,I²=0%)。
- 在全部 5 项评估 MCAO 后第 7 天结局的研究中,与溶媒相比,IRL-1620 与统计学显著更低的神经功能缺损和更好的运动表现相关。
- IRL-1620 给药还改善梗死体积、神经祖细胞分化潜能和线粒体命运。
证据类型、等级与局限
- 证据类型:系统评价与 Meta 分析,纳入研究均为动物大鼠模型;原文未报告证据等级或推荐强度。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在动物 MCAO 模型中 IRL-1620 增强神经发生和神经保护并改善结局;未来需在人急性缺血性卒中及心脏骤停等其他常见脑缺血病因中扩展研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sovateltide (IRL-1620), an endothelin B receptor agonist, has previously demonstrated neuroprotective and neuroregenerative effects in animal models of acute ischemic stroke. Recently, clinical trials indicated that it could also be effective in humans with stroke. Here, we systematically investigate whether IRL-1620 may be used for the treatment of ischemia-induced brain injury.
METHODS: A systematic review was performed following the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. MEDLINE (PubMed) and Scopus databases were searched for eligible studies up to December 2022. The databases ClinicalTrials.gov and Pharmazz Inc. were screened for unpublished or ongoing trials. Only studies in English were evaluated for eligibility. Meta-analysis of the included studies was also conducted.
RESULTS: Finally, seven studies were included in the review, all in animal rat models because of scarcity of clinical trials. Six studies, all in middle cerebral artery occlusion (MCAO) models, were selected for meta-analysis. In the two studies assessing mortality, no deaths were reported in the IRL-1620 group 24 h after MCAO, whereas the vehicle group had almost a five times higher mortality risk (risk ratio 5.3, 95% confidence interval 0.7-40.1, I2 = 0%). In all five studies evaluating outcome on day 7 after MCAO, IRL-1620 was associated with statistically significantly lower neurological deficit and improved motor performance compared with the vehicle. Infract volume, differentiation potential of neuronal progenitor cells, and mitochondrial fate also improved with IRL-1620 administration.
CONCLUSIONS: According to the above, in animal MCAO models, IRL-1620 enhanced neurogenesis and neuroprotection and improved outcome. Future studies are needed to expand our understanding of its effects in human study participants with acute ischemic stroke as well as in other common causes of cerebral ischemia including cardiac arrest.
参考来源
- Moustakas D, Mani I, Pouliakis A, et al. The Effects of IRL-1620 in Post-ischemic Brain Injury: A Systematic Review and Meta-analysis of Experimental Studies. Neurocrit Care. 2024. PMID: 38724864. doi:10.1007/s12028-024-01994-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。